The key factors driving the growth of this market are the growing prevalence of chronic diseases (such as cancer, diabetes, and cardiovascular diseases), favorable reimbursement scenario in major markets, and technological advancements in injector devices.
The global Wearable
Injectors Market is projected to reach USD 9.41 billion by
2023 from USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast
period (2018-2023).
Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100771004
On the basis of type, the wearable
injectors market is segmented into on-body and off-body injectors. The on-body
injectors segment is expected to account for the larger market share in 2018,
while the off-body injectors segment is projected to witness the highest growth
rate during the forecast period. The drawbacks associated with on-body wearable
injectors, such as painful removal, skin sensitivity issues and irritation, and
adhesive fitting issues have resulted in the increased adoption of off-body
injectors.
On the basis of therapy, the wearable
injectors market is segmented into immuno-oncology, diabetes, cardiovascular
diseases, and other therapies (Parkinson’s disease, thalassemia, and primary
immunodeficiency disorders). In 2018, the immune-oncology segment is expected
to account for the largest share of the wearable injectors market.
In 2018, North America is expected to
account for the largest share of the wearable injectors market, followed by
Europe.
Speak To Analyst: - https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=100771004
The key players in the global wearable
injectors market are Amgen (US), Medtronic (Ireland), Insulet Corporation (US),
Tandem Diabetes Care (US), United Therapeutics Corporation (US), Valeritas
(US), and SteadyMed Therapeutics (US). The other prominent players in this
market are Ypsomed (Switzerland), Becton, Dickinson and Company (US), Enable
Injections (US), Sensile Medicals (Switzerland), and Bespak (UK).
No comments:
Post a Comment